The Role of RWE in Addressing Underrepresented Patients in CDK4/6 Inhibitor RCTs

Dr. Adam Brufsky talks about the role of real-world evidence in addressing limitations of CDK4/6 inhibitor randomized clinical trials, particularly for underrepresented patients.
This video is part of a larger CE/CME Certified program entitled: RWE Where RCTs Fall Short: Optimizing Frontline Treatment of HR+/HER2- Metastatic Breast Cancer. You can receive free CME credit, view this video, and download slides from the presentation at www.mededonthego.com/Video/pr...